Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
31 August 2022 | Story Prof Motlalepula Matsabisa | Photo Andrè Damons
Prof Motlalepula Matsabisa
Prof Motlalepula Matsabisa, Professor and Director of Pharmacology, Faculty of Health Sciences, University of the Free State. He is also leading Africa’s fight against the COVID-19 pandemic after being appointed as chairperson of the World Health Organisation’s (WHO’s) Regional Expert Advisory Committee on Traditional Medicines for COVID-19.

Opinion article by Prof Motlalepula Matsabisa, Professor and Director of Pharmacology, Faculty of Health Sciences, University of the Free State.
As we celebrate African Traditional Medicine Day on 31 August to promote the important role of the continent’s rich biodiversity in improving well-being, one needs to acknowledge the role that COVID-19 played in shining a spotlight on African traditional medicines (ATMs). Responding to the pandemic, rapid vaccine research and development and the repurposing of drugs in the fight against COVID-19 happened on great scales. Traditional medicines also benefited from renewed interest as a possible solution for this deadly disease. This year the World Health Organisation (WHO) Regional Director has approved the theme for the celebration of the 20th anniversary of African Traditional Medicine Day as ‘Two Decades of African Traditional Medicine Day: Towards Achieving Universal Health Coverage’. Countries will be celebrating individually, while WHO will hold a virtual celebration on the day. 

Even though ATMs, similarly to other traditional medicines such as those from China and India, have been used by African people long before the advent of “modern” medicine, and still continue to be used for the treatment of a range of diseases, most people still do not believe in its value as medicines for serious and chronic illnesses. This might be because of the lack of scientific research behind these remedies, and the dominance of the Western knowledge system and its wide acceptance by younger generations who value more Western values and lifestyles while being oblivious to ATMs. But in Africa, where about 80% of the population are said to rely on traditional medicine for their basic healthcare needs (according to the WHO), ATMs should be given a more prominent role. They should be more visible on shelves in big pharmacies, prescribed by healthcare practitioners beyond just traditional health practitioners (THPs), and should be more mainstreamed than what is currently the case. 

UFS Department of Pharmacology made great strides researching ATMs

Over the past few years, the University of the Free State (UFS), through its Department of Pharmacology, has made great strides in researching the possibilities and potential of ATMs. My team and I, together with other role-players in the institution, are in the process of establishing one of the most advanced modern pharmacology GLP-accredited research and development laboratories in the country, and possibly in the region, after receiving a grant of R58 million from the government. The UFS is recognised as a national leader in pharmacology as well as research and development of indigenous knowledge systems (IKS) and traditional medicines. The UFS has developed and built infrastructure in this field of scientific research, and has the best modern equipment for the training, teaching, and development of prototypes and products for commercialisation based on IKS. Interdisciplinary and interfaculty research is undertaken in this study area, and we have an excellent track record of sound community engagement with relevant stakeholders. 

The department has also been awarded an annual Technology and Innovation Agency Platform (TIA) grant of R17 million for the next five years. This research and teaching programme, known as African Medicines Innovations and Technologies Development (AMITD), will help to recruit and employ the best skills throughout the research, development, and herbal-medicine manufacturing value chains. We received a DSI high-end infrastructure (HEI) grant to build a laboratory, which will be a centre of excellence for the government, the WHO, and the African Union’s Commission for Social Development. The grant will also be used to build a herbal medicines production facility, as well as to pilot a health facility for traditional medicines. I am pleased that a multinational private pharmaceutical company has come forward and will be collaborating with us to realise these plans – joint manufacturing and business development, and joint engagement in the integrated health facility. We are now, together with the WHO and the aforementioned company, entering into a collaboration agreement to work together on key projects in traditional medicine manufacturing and training. 

Traditional medicine therapies emerged as possible cures or remedies for COVID-19

As part of the COVID-19 response, traditional medicine therapies have emerged as possible cures or remedies for the deadly disease. The pandemic has certainly helped to improve the profile of ATMs. In Cameroon, for example, two complementary therapy products for COVID-19 have been approved by the government, while Madagascar’s herbal remedy, COVID-Organics Plus Curative, has been in phase II clinical trials.  Encouraging preliminary results have been reported around this clinical trial. Similar trials on traditional medicine products for COVID-19 – conducted according to WHO protocols – are also underway in other African countries, including Democratic Republic of Congo, Nigeria, Uganda and South Africa, according to the World Health Organisation (WHO).

With regard to South Africa, my team and I and FARMOVS received approval from the South African Health Products Regulatory Authority (SAHPRA) to conduct the first multicentre controlled phase II clinical trial of a plant-based product, PHELA, on mild- to moderate-symptom COVID-19 patients.

The main purpose of the clinical trial is to confirm that the product can treat COVID-19 and be registered by the South African Health Products Regulatory Authority. We confirmed in vitro and in vivo that the medication works as an immune modulator to modulate the cytokine storm due to COVID-19, and also restores and normalises the patient’s immune system. This pivotal study is based on the modification of the WHO master protocol for clinical trials. The study is ongoing at three sites, and we are considering the addition of two more sites, to make a total of five clinical-trial sites. The development of PHELA has taken place under stringent scientific scrutiny in both preclinical and clinical research. The efficacy of PHELA as both an immune modulator and an anti-SARS-COV-2 treatment has been proven in in vitro and in vivo studies with reproducible results, conducted by three independent research institutions and a science council. PHELA is a herbal product made of four medicinal plants. Traditionally PHELA has been claimed for use for a historical disease called muyaga, but recently it has been scientifically tested and found effective as an immune modulator that benefits persons with a compromised immune system.

African Traditional Medicines Day: a reminder of the value and contribution of traditional medicines

The celebration of African Traditional Medicines Day annually on 31 August reminds all of us of the value and contribution of traditional medicines. This year’s theme on the role of ATMs in universal health coverage (UHC) is most befitting, as we know that medicines from natural products are affordable, accessible, have almost no side effects, and are proven enough because they have been advised for many generations, and they have been quite efficient in treating 90% of all currently known human diseases. The annual celebration, therefore, aims to gain more support for the continent to fast-track the research and development, as well as the local manufacturing, of well-researched ATM products, and for them to be made available through our national health systems. This also encourages the training of younger generations in this field of science and research.

Support for local manufacturing of ATMs will help bring traditional medicinal products into mainstream health systems and formal economies, creating jobs and wealth throughout all the ATM-manufacturing value chains – commercial cultivations, research and development, manufacturing, distribution, logistics, and marketing. This will help move the continent from dependency on aid from rich Western countries. Aid has not given Africans any independence, and has never been sustainable. It is, instead, enslaving the continent. If we want to be independent of big Western pharmaceutical companies and their expensive medicines, inequities and discrimination – as seen during the COVID-19 pandemic, African countries were left wanting when it came to access to personal protective equipment, diagnostics, therapeutics, and vaccines – Africa does not need aid. We need technical skills, technology development, and skill transfer. Aid makes African dependent, not independent. We need investment –  financial, research and resources – into developing our own, locally and regionally sourced herbal-based medicine. Africa and her people need African solutions to its health problems –and who could be better suited to create them than the continent’s people through its indigenous knowledge systems. 

Africa should be a leading force 

In August health ministers from Africa met at a special event – the WHO Health Ministers Regional Committee for Africa, in Lomé, Togo. The theme of the meeting was ‘Building Back Better: Rethinking and rebuilding resilient health systems in Africa to achieve UHC and health security’. The WHO Africa Regional Office hoped to develop a collective roadmap for building resilient health systems through integrated efforts that coordinated actions across all clusters and teams in the WHO’s regional office and country offices, and with national, regional and global partners supporting African countries as they ramp up efforts to recover from the pandemic-induced disruption and build back better toward achieving UHC and being prepared for future health emergencies.

As Chairperson of the Regional Advisory Committee on Traditional Medicine for COVID-19 Response (REACT), I gave a presentation on fast-tracking research and development and local production of herbal medicines during the second session, with the theme ‘Lessons to guide strengthening of health product manufacturing in Africa’. I am of the view that COVID-19 helped to prepare the continent for the next major event, and Africa will be better suited to deal with it. We cannot, again, be caught off guard and found wanting, and be at the mercy of the West for donations. I presented ways to put in place systems for supporting local manufacturing of therapeutics, with participation through the African regional economic blocks. 

News Archive

Prof Frederick Fourie to step down as UFS rector
2008-09-08

“It is with sadness that I hereby announce my intention to step down as rector and vice-chancellor of the University of the Free State (UFS) in the 4th quarter of this year.

Obviously this decision has not been taken lightly. After careful consideration I am, however, convinced that this is as far as I can take the UFS as vice-chancellor and rector. This flows primarily from the exhausting times that I have experienced during the past nine years, first as vice-rector (since 1999) and then as rector (since 2003), in managing and implementing several complex strategic projects.

The challenges and complexities of continuous change management at a higher education institution, and specifically the demands of further dynamic development and transformation at the UFS, demand enormous amounts of emotional energy and drive. For me the stress due to, especially, the political divisions and tensions in the UFS Council and the broader university community during the past year has been extremely draining. The broader institution and its people also show signs of trauma.

I think it is time for new and fresh leadership, especially in the light of the transformation challenges of the UFS.

I have thus decided to step down in the interest of transformation and the further dynamic development of the UFS.

Having been on sabbatical leave since May, I will not return to take up my post. I will remain on leave until my official date of retirement from office. (The exact date must still be determined.)

I am grateful for the opportunity to have been at the helm of the UFS and to help the institution cross several bridges. During the past nine years I have been privileged to lead large strategic projects together with many dedicated and talented UFS colleagues. It has been a wonderful experience of thinking and working together in order to elevate the functioning of the University to new levels in several key areas.

One of the most important projects was the financial turnaround strategy of 2000-2005, which took the UFS from a financial crisis to a situation where currently it annually has almost R100 million of discretionary funding available to spend on strategic projects, and where staff remuneration and promotion opportunities have increased dramatically since 2000. In this period the UFS has also grown from approximately 10 000 students to more than 27 000 in 2008.

A second was the strategy to invest strongly in the academic core and notably research, research capacity and research apparatus. Since 2003 research outputs have increased by approximately 50% - a significant accomplishment of our researchers and faculties. In conjunction with this, the launch of the six strategic academic clusters (focus areas) should create the basis for the continued growth in the national and international stature of the UFS in future. The development of the national leadership role of the UFS with regard to community service also was a special and successful project.

A third large strategic project was the progress with regard to diversity, the balanced multilingualism policy in the academe as well as the administration, the employment equity plan, the UFS transformation plan and especially the institutional charter – which could lay the foundation for a university where one and all can experience a true sense of belonging amidst diversity. These have been important steps that we can feel proud of (although much work obviously remains with regard to non-racialism and also non-sexism).

As far as residences are concerned, it was historically significant that this time, in contrast to 1997/8, the UFS succeeded in crossing the bridge of diversity and integration in residences – with due regard to the difficulties we faced. Hopefully this will considerably ease the task of my successor and her/his management team in managing diversity and in pursuing best practice transformation.

A fourth large project was the large-scale upgrading and development of infrastructure, academic buildings and facilities as well as support service facilities, student facilities and pedestrian walkways. The objective was a campus of the highest quality and aesthetics to effect a lasting improvement in their work- and living environment for staff and students. Indeed, the UFS Main Campus today is seen as an example of sensitive and high quality campus planning.

Other initiatives which haven’t borne fruit yet are, for example, those with regard to entrepreneurial activities, sport development and sport business development, and the possible establishment of an engineering programme or faculty at the UFS.

On the whole the most important thing for me has been the progress in establishing a deep commitment to quality and equity/fairness and in boosting the national and international profile of the UFS as a high quality progressive university. Of course, justice, equity and quality intrinsically are challenges which require daily dedication to make it an ingrained habit.

I wish to thank all those people with whom I could work during the past years in tackling large and complex challenges with mutual loyalty, shared wisdom and effort – from the Financial Turnaround Team to the Exco, the Executive Management, the Faculties, the Senate, support service divisions, the University Council and several committees and task teams”.

Frederick C.v.N. Fourie
Rector and Vice-Chancellor
University of the Free State

Prof Frederick Fourie has been with the UFS since 1976. After obtaining a PhD in Economics from Harvard he was appointed professor at the age of 29 in 1982, head of the Department of Economics in 1992, Distinguished Professor in 1998, Dean of the Faculty of Economic and Management Sciences in 1997, Vice-rector: Academic in 1999 and vice-chancellor in 2003.

Media Release
Issued by: Lacea Loader
Assistant Director: Media Liaison
Tel: 051 401 2584
Cell: 083 645 2454
E-mail: loaderl.stg@ufs.ac.za  
8 September 2008
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept